Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Beijing Creatron Institute Of Pharmaceutical Research Co. Ltd. is currently navigating the patent prosecution process within the Biotechnology & Pharmaceuticals technology area. The company has 1 pending office action, indicating a specific current engagement with the patent office. This action is being handled by 1 distinct examiner within 1 distinct art unit, which centralizes the technical review of the current application. Such a focused profile suggests a targeted technological goal.
The busiest examiner for this portfolio is CHO, DAVID H, who is currently overseeing 1 pending office action. Because there is 1 distinct examiner and 1 distinct art unit involved, the company's immediate prosecution success is contingent upon the specific feedback from this individual. This concentration simplifies the monitoring process but also focuses procedural risk on the point of examination within the Biotechnology & Pharmaceuticals sector.
Practitioners managing this portfolio can focus resources on the specific requirements of CHO, DAVID H. The presence of 1 pending office action suggests that the technology being patented is specialized. With 1 pending case under the busiest examiner, the administrative requirements are low, allowing for a dedicated focus on the technical merits of the case. This allows for a deep technical dialogue to resolve the pending matter.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHO, DAVID H | 1 | 31.9% | +67.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18029062 | SGLT-2 INHIBITOR SARCOSINE CO-CRYSTAL, PREPARATION METHOD THEREFOR AND USE THEREOF | CHO, DAVID H | 9d |
| Art Unit | Apps |
|---|---|
| 1693 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18029062 | SGLT-2 INHIBITOR SARCOSINE CO-CRYSTAL, PREPARATION METHOD THEREFOR AND USE THEREOF | CHO, DAVID H | 1693 | §103 | Final Rejection | 9d | Pending | Mar 28, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial